The gold standard for psychedelic investment. A virtual psychedelic investment conference covering the top companies, the latest IPOs, the newest opportunities & the deepest insights.
Bill joined Haywood Securities in 2003 after an institutional equity sales role at Credit Suisse First Boston and National Bank Financial. Prior to that, he was an associate equity analyst in the gold sector at First Marathon Securities.
Dr. Ivan Casselman
Chief Psychedelic Officer, HAVN Life
Dr. Ivan Casselman, PhD is a psychedelic medicine researcher with over a decade of experience in academia. His research spans the human use of psychedelics, ethnobotany, ethnopharmacology and the study of plant science including genetics and analytical chemistry. One of the key components to his research has been a focus on ethnography, experiential investigation and ensuring a comprehensive understanding of the human psychedelic interface. Dr. Casselman is also experienced in nutraceutical formulation and has designed several products now available in legal Cannabis markets in North America. Dr. Casselman’s experience in the development of herbal formulations, authentication, and quality control gives him a unique insight into the development of plant-based medicine products across a wide variety of commercial applications. In addition to his cannabis industry experience, he has been involved in the start-up, growth and expansion of several plant medicine and herbal retail companies in Canada, the United Kingdom, and Australia.